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Abstract
Background: Because treatment of advanced gastric cancer (AGC) patients after failure with first-
line chemotherapy remains controversial, we performed this retrospective analysis based on the
data obtained from 1455 patients registered in a first-line treatment cohort with respect to
receiving or not receiving subsequent chemotherapy.
Methods: The decision for administering second-line chemotherapy was, in most cases, at the
discretion of the physician. Seven-hundred twenty-five (50%) received second-line chemotherapy
after first-line failure. Univariate and multivariate analyses were performed on the recognized
baseline parameters for survival.
Results: At the time of initiating second-line chemotherapy, the patients' median age was 56 years
(range, 22 to 86) and 139 (19%) had an Eastern Cooperative Oncology Group (ECOG)
performance status of 2 or more. Seven (1%) complete and 108 (15%) partial responses to second-
line chemotherapy were observed for an overall response rate of 16% (95% confidence interval
[CI], 13 to 19%). The median progression-free and overall survivals, calculated from the start of
second-line chemotherapy, were 2.9 months (95% CI, 2.6 to 3.3) and 6.7 months (95% CI, 5.8 to
7.5), respectively. Multivariate analysis revealed that low baseline hemoglobin level (hazard ratio
[HR], 0.74; 95% CI 0.61–0.90) and a poor performance status (HR, 0.66; 95% CI, 0.52–0.83) were
independent negative prognostic factors for overall survival.
Conclusion: Performance status, along with baseline hemoglobin level, could be used to identify
the subgroup of patients most likely to benefit from second-line chemotherapy for AGC.
Published: 9 April 2009
BMC Cancer 2009, 9:110 doi:10.1186/1471-2407-9-110
Received: 6 October 2008
Accepted: 9 April 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/110
© 2009 Ji et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:110 http://www.biomedcentral.com/1471-2407/9/110
Page 2 of 6
(page number not for citation purposes)
Background
Gastric cancer is the most frequently occurring malig-
nancy in Korea, and is one of the main causes of cancer
death [1]. For patients with recurrent, metastatic, or
advanced gastric cancer (AGC), chemotherapy can
improve survival, and possibly, provide significant pallia-
tion of symptoms [2,3]. However, over half of patients
with AGC who received chemotherapy failed to achieve
response and even in these responders, the duration of
responses was as short as a few months [4]. Given no
standard salvage treatment available in those patients,
limited investigation on second-line chemotherapy after
first-line failure has been performed [5-7]. The sample
size of most studies was small and randomized trial com-
paring chemotherapy and best supportive care was not yet
performed [8].
Despite the lack of evidence for benefit associated with
administering salvage chemotherapy, it is a common
practice to offer further chemotherapy for AGC patients
after first-line failure, because patients and physicians
have difficulty with accepting only supportive care with-
out the possibility of systemic anticancer effects. In gen-
eral, chemotherapy in AGC should be used to prolong
survival and improve the quality of life (QOL) of the
patients, a factor that is even more important in the case
of salvage treatment. Administration of an active and tol-
erable chemotherapy regimen in a well-selected patient
population may have a beneficial effect on QOL, as a
direct result of improvements in clinical outcome. There-
fore, the knowledge of prognostic and predictive factors,
which may contribute to the identification of the subset of
patients with a greater likelihood of a benefit from sec-
ond-line therapy, could be useful. Because well-designed,
randomized, controlled clinical trials are lacking in
patients with AGC, an exploratory, pooled analysis of
small studies or retrospective analysis seems to be an
important source of data to allow the definition of opti-
mal treatment, enhance patient counseling, and generate
hypotheses for future studies.
In an effort to define the potential role of the second-line
chemotherapy in AGC, we performed this retrospective
analysis based on the data obtained from 1455 patients
registered in our previous retrospective study [9]. The
present evaluation was also done with the intent to plan
and develop improved therapeutic strategies for AGC
patients after first-line failure.
Methods
We collected follow-up patient data from our cancer reg-
istry. We previously performed a retrospective study on
1455 AGC patients who were treated with first-line chem-
otherapy between September 1994 and February 2005
[9]. All patients had been treated with taxanes- and/or
fluoropyrimidine-based combination regimens as their
first-line therapy for advanced disease. All the data was
prospectively recorded and only the outcome results were
updated at the time of analyses. Written informed consent
was given by all patients prior to receiving chemotherapy,
according to institutional guidelines. This retrospective
study was reviewed and approved by the Samsung Medi-
cal Center institutional review board (Seoul, Korea).
The decision for administering second-line chemotherapy
was, in all cases, at the discretion of the physician. The sec-
ond-line chemotherapy regimen to be used was deter-
mined by the treating physician but, in about half of the
patients, in the context of second-line clinical trials.
Chemotherapy was repeated every 2–3 weeks according to
the regimen. All tumor measurements were assessed after
every 2 or 3 courses of chemotherapy, by using abdomi-
nopelvic computed tomography (CT) scan and other tests
that were used initially to stage the tumor. Tumor
response was evaluated and reviewed by an investigator
(SHJ) at the time of analysis, according to the Response
Evaluation Criteria for Solid Tumors (RECIST) [10].
The primary endpoint of this study was overall survival
(OS). The starting point of OS and progression-free sur-
vival (PFS) was the first day of second-line chemotherapy.
The date of disease progression or death from causes other
than AGC was used in calculating PFS. Time to death,
whatever the cause, was used to calculate OS. PFS and OS
were estimated according to the Kaplan-Meier method
and the statistical significance of survival curves between
the two groups was tested with a log-rank test. Treatment-
free interval was measured from the end of first-line
chemotherapy and the start of second-line chemotherapy.
To examine the impact of clinical and treatment variables
on the outcomes of second-line chemotherapy, multivar-
iate Cox regression models were used. Covariates
included were age (below vs. ≥ median), gender, previous
gastrectomy, an Eastern Cooperative Oncology Group
(ECOG) performance status (0–1 vs. ≥ 2), weight loss
(>5%) before treatment, best response to first-line chem-
otherapy, treatment-free intervals (below vs. ≥ median),
number of involved sites (one vs. ≥ 2), metastases (liver,
bone, and bone marrow), presence of ascites, baseline
chemistry profiles (serum albumin, alkaline phosphatase,
and bilirubin), and hemoglobin levels. Laboratory
parameters were initially recorded as continuous variables
and later dichotomized according to the median value of
each variable (below vs. ≥ median). All P values were two-
sided, with P < 0.05 indicating statistical significance.
Results
Patient characteristics are given in Table 1. Seven hundred
twenty-five (50%) received second-line chemotherapy after
first-line failure. For patients who received supportive careBMC Cancer 2009, 9:110 http://www.biomedcentral.com/1471-2407/9/110
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only, reasons for a such decision was available in 609
patients, the main reasons being poor performance status
(71%) and patient's refusal (29%). About one-thirds of
patients had two or more metastatic disease sites, mostly
involving peritoneum and abdominal lymph node. Bone
marrow aspiration and biopsy were performed if clinically
suspected (n = 69), and a bone marrow involvement was
found in 41 patients. Nineteen percent of patients with an
ECOG performance status ≥ 2 received second-line chemo-
therapy. Thirty percent of patients (n = 218) were treated
with monotherapy (oral fluoropyrimidines, irinotecan or
taxanes), and others received second-line chemotherapy
with combination regimens. The most commonly used
combination chemotherapy regimen was taxanes/cisplatin
(n = 144), followed by the combination of oxaliplatin and
leucovorin/fluorouracil (FOLFOX, n = 113), irinotecan-
based (n = 109), anthracycline-based (n = 77), and fluoro-
pyrimidine/cisplatin (n = 64). Further third-line chemo-
therapy was offered to 215 patients (30%) after second-line
failure.
Of a total of 725 patients, 105 could not be evaluated for
responses because of the absence of any measurable
lesions or early discontinuation of therapy. Objective
responses to second-line chemotherapy were noted in 115
patients (response rate, 16%; 95% confidence interval
[CI], 13 to 19%) out of which seven were complete
responses. Patients who had a poor performance status (≥
2 in ECOG scale) were significantly less likely to respond
to second-line chemotherapy (9% vs. 21%; p = 0.016)
compared to those with an ECOG performance status of 0
or 1. Other factors associated with lack of optimal
response were the presence of ascites (8% vs. 20%; p =
0.018) and bone marrow involvement (0% vs. 20%; p =
0.038). Response rate was not significantly influenced by
age, gender, weight loss, baseline laboratory parameters,
bone or liver metastasis, prior response to first-line chem-
otherapy, or treatment-free interval.
Of the 725 patients included in this analysis, 699 (96%)
died. The estimated median PFS was 2.9 months (95% CI,
2.6 to 3.3) and median OS was 6.7 months (95% CI, 5.8
to 7.5). In the univariate model, the estimated OS was sig-
nificantly shorter for patients with low baseline hemo-
globin, ascites, and a poor performance status (Table 2).
In the Cox regression model, independent prognostic
Table 1: Patient characteristics at the time of second-line chemotherapy
No. of patients (n = 725)
Median age (range), years 56 (22–86)
Male gender 473 (65%)
Prior therapy
Surgery 364 (50%)
Adjuvant chemotherapy ± radiotherapy 145 (20%)
First-line chemotherapy*
FP (± leucovorin) or XP 402 (56%)
ECF or ECX 29 (4%)
Taxane (paclitaxel or docetaxel) + cisplatin 252 (35%)
Irinotecan- or oxaliplatin-based 42 (6%)
Response to first-line chemotherapy
Responder 143 (20%)
Non-responder or unknown 582 (80%)
Treatment-free interval, months
Median (range) 2 (1–26)
ECOG† performance status
0–1 586 (81%)
2 or more 139 (19%)
Involved site(s)
Two or more involved sites 283 (39%)
Ascites 193
Liver metastasis 139
Bone marrow involvement (n = 69) 41
Baseline laboratory parameters, median
Hemoglobin, g/l 9.8
Albumin, g/dl 3.4
Alkaline phosphatase, U/l 86
Bilirubin, mg/dl 0.5
Calcium, mg/dl 8.9
*FP, 5-fluorouracil + cisplatin; XP; capecitabine + cisplatin; ECF, epirubicin + cisplatin + 5-fluorouracil; ECX, epirubicin + cisplatin + capecitabine; 
†ECOG, Eastern Cooperative Oncology Group.BMC Cancer 2009, 9:110 http://www.biomedcentral.com/1471-2407/9/110
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parameters for OS were performance status and hemo-
globin level (Table 3). We also tested whether the survival
was modified by interaction between the effect of other
significant clinical parameters and performance status; the
first-level interaction term between these variables was
entered into separate multivariate model. However, the
result was not significant. The correlation between per-
formance status and hemoglobin level was not significant
(correlation coefficient, 0.048; P = 0.308). This model
suggests that AGC patients with low hemoglobin (<9.8 g/
l) and poor performance status prior to the initiation of
second-line chemotherapy have a risk of death that is two
times than that of patients with hemoglobin ≥ 9.8 g/l and
an ECOG performance status of 0 or 1.
For exploratory purposes, we compared OS according to
second-line chemotherapy regimens given. Of 218
patients who were treated with second-line single-agent
therapy, OS was longer, although statistically insignifi-
cant, in patients who received irinotecan or taxane (9.3
months and 8.3 months, respectively) than oral fluoropy-
rimidines (6.2 months; P = 0.245). However, no relevant
OS difference between patients who received mono-
therapy (median, 6.8 months; 95% CI, 5.1 to 8.4) and
combination regimens (median, 6.7 months; 95% CI, 5.7
to 7.6) was detected (P = 0.373). On the other hand, OS
was significantly longer in patients received third-line
chemotherapy (median, 11.5 months; 95% CI, 10.8 to
12.1) than those who were not treated further (median,
4.9 months; 95% CI, 4.5 to 5.4; P < 0.001).
Discussion
The present analysis of 725 AGC patients who were
treated with second-line chemotherapy has demonstrated
a strong association between some baseline parameters
(i.e., hemoglobin level and a performance status) and OS.
The response rate achieved with second-line chemother-
apy was 16%. Although this study is retrospective in
Table 2: Univariate analysis according to baseline clinical parameters
OS, mo* 95% CI P
Previous gastrectomy No 6.7 5.3 to 8.2 .660
Yes 6.7
Gender Male 7.1 5.9 to 8.4 .464
Female 6.6 5.9 to 7.3
Age < median 7.1 5.9 to 8.4 .243
≥ median 6.5 5.9 to 7.3
Response to first-line chemotherapy No 6.4 5.5 to 7.2 .432
Yes 7.1 5.9 to 8.4
Treatment-free interval < median 6.7 5.8 to 7.6 .863
≥ median 6.8 5.4 to 8.1
Performance status 0 or 1 7.1 6.2 to 8.1 .001
≥ 2 5.4 3.8 to 7.1
Albumin < median 6.5 5.2 to 7.5 .553
≥ median 7.1 5.9 to 8.3
Alkaline phosphatase < median 6.5 5.7 to 7.4 .886
≥ median 7.1 5.6 to 8.6
Bilirubin < median 6.2 5.3 to 7.1 .766
≥ median 7.1 5.9 to 8.4
Calcium < median 7.2 6.0 to 8.3 .210
≥ median 5.9 5.1 to 6.8
Hemoglobin < median 5.8 5.6 to 6.4 .004
≥ median 8.1 7.1 to 9.1
No. of involved site(s) 1 6.7 5.5 to 8.0 .225
≥ 2 6.4 5.4 to 7.3
Liver metastasis No 7.4 5.2 to 9.6 .497
Yes 6.6 5.8 to 7.5
Bone metastasis No 8.4 5.2 to 11.6 .793
Yes 6.6 5.9 to 7.4
Ascites No 7.1 6.2 to 8.1 .038
Yes 4.7 3.5 to 5.9
Bone marrow involvement No 6.7 5.9 to 7.6 .555
Yes 5.0 2.5 to 7.6
Weight loss No 6.7 5.8 to 7.5 .853
Yes 6.6 3.4 to 9.9
* OS, median overall survival; 95% CI, 95% confidence interval.BMC Cancer 2009, 9:110 http://www.biomedcentral.com/1471-2407/9/110
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nature, the results provide a piece of evidence that patients
with first-line chemotherapy failure may derive a benefit
from second-line chemotherapy.
AGC is an incurable condition where the aim of treatment is
to improve survival and to palliate symptoms. Disease may
respond to several types of chemotherapy initially, and these
treatments have been shown to provide palliation as indi-
cated by improvement in duration and/or quality of survival
[2,3]. However, when patients do not respond to chemo-
therapy or eventually develop disease progression, no estab-
lished second-line therapy can be offered. There is no
evidence that second-line chemotherapy in patients with
AGC will result in substantial prolongation of survival and
there is potential for toxicity from the treatment. At the time
of first-line chemotherapy failure, at least half of the AGC
patients are candidates for further treatment. Although it is
recognized that there is a declining probability of response
with subsequent chemotherapy regimens, favorable out-
comes seen in some phase II trials of second-line chemother-
apy for AGC[8] In a recent report, we focused on the QOL
issues and demonstrated that second-line chemotherapy
may be of value [11]. Clearly, second-line chemotherapy
may not be beneficial for all patients. It is necessary to better
define the sub-population of patients who may benefit from
second-line chemotherapy because there is also potential for
toxicity and adverse effects from the treatment. Therefore, the
identification of factors allowing the selection of patients
who are likely to benefit from second-line chemotherapy is
an important challenge.
In a pooled analysis of 3 randomized trials, Chau et al
[12] investigated the prognostic significance of the base-
line factors in 1080 chemotherapy-naïve patients with
esophagogastric cancer. They found that poor perform-
ance status, metastases to liver and peritoneum, and alka-
line phosphatase significantly predicted poor survival.
Our previous retrospective study in 1455 AGC patients
have revealed that poor prognostic factors were no previ-
ous gastrectomy, low albumin, high alkaline phos-
phatase, bone metastasis, the presence of ascites, and a
poor performance status [9].
In the current study, hemoglobin level, as well as perform-
ance status, emerged as the significant survival predictor.
When interpreting the results, it is of note that this analy-
sis represents only a small sample of patients and half of
them had low hemoglobin level at presentation. In this
study, we cannot completely exclude the possibility that
lower levels of performance status may be reflective of
other occult predictors for a poor prognosis. It is possible
that sick patients (i.e., patients with a low hemoglobin
level and limited survival) may be socially inactive. How-
ever, the correlation between performance status and
hemoglobin level was not significant.
Low hemoglobin level, in the presence or absence of treat-
ment, is a common finding among AGC patients [13]. A
number of factors contribute to the high incidence of can-
cer-related anemia. These include not only chemotherapy
and radiation-induced myelosuppression, but also bleed-
ing, hemolysis, marrow infiltration by tumor, nutritional
deficiencies, and cytokine-mediated anemia of chronic
disease. The results of the present analysis strongly suggest
that patients with poor performance status and/or low
hemoglobin level rarely benefited from second-line
chemotherapy. It is indicated that second-line chemother-
apy in these patients should be given in caution and con-
sideration should be warranted to exclude such patients
from future clinical trials.
Besides clinical parameters, appropriate patient selection
based on molecular markers is one of the most extensively
studied areas in clinical research. While it is still at an early
stage and it would take years before we can see clinical
application, extensive work is ongoing to identify possible
molecular markers, including epidermal growth factor
receptor (EGFR) or vascular endothelial growth factor
(VEGF) expression [14,15], Her2/neu amplification [16],
and excision repair cross-complementing gene 1 (ERCC1)
[17], that could be linked to sensitivity or resistance to
specific agents, as well as specific genotype variations har-
bored in different ethnicities.
Although it would be difficult to choose the best second-
line chemotherapy regimen from the results of the current
study or others, the choice a survival benefit from combina-
tion chemotherapy seems unlikely, as there was no signifi-
cant OS difference between patients who were treated with
monotherapy and combination. In salvage setting, the
choice of a second-line agent depends on first-line treat-
ment. Because many AGC patients have received first-line
chemotherapy with fluoropyrimidine/platinum combina-
tion, it seems more prudent to avoid these agents in salvage
regimen for reasons of efficacy. Given these considerations,
our next step will be to compare single-agent chemother-
apy with best supportive care in pretreated AGC patients
and to investigate prospectively the relative place of the sec-
ond-line chemotherapy in the treatment of AGC.
Conclusion
Selected AGC patients with good performance status
should be considered for second-line chemotherapy after
Table 3: Multivariate analysis according to baseline clinical 
parameters
P Hazard ratio 95% CI
Presence of ascites 0.704 0.945 0.706 to 1.266
Low hemoglobin 0.002 0.741 0.611 to 0.898
Poor performance status 0.001 0.656 0.516 to 0.834Publish with BioMed Central    and   every 
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first-line failure. Our results show that performance status,
along with hemoglobin level, at the time of second-line
chemotherapy initiation may provide useful information
to predict outcome in AGC patients. With better patient
selection, clinical outcomes of AGC patients in second-
line setting can be improved. Prospective clinical trials
investigating clinical outcomes in association with known
prognostic factors such as performance status may be war-
ranted. Furthermore, emerging science and the knowledge
of disease may further guide us to develop individualized
treatment for AGC patients.
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